Key Takeaways
- Academic Centers of Excellence can influence diagnosis, referral, education, guidelines and adoption far beyond the patients they personally manage.
- Map referral networks early—community entry points often differ from where treatment decisions occur.
- Medical Affairs engagement with Centers of Excellence should begin before promotional launch activity.
- Rare disease commercialization is a network problem, not simply a territory coverage problem.
Rare disease markets are often defined not simply by patient numbers, but by where expertise is concentrated.
Academic Centers of Excellence can have a disproportionate influence on diagnosis, research, referral, physician education, treatment decisions, guidelines and adoption. Understanding this ecosystem can materially change commercialization strategy. See rare disease commercialization consulting.
Expertise Is Concentrated
When a disease is uncommon, community physicians may encounter few cases. Patients are therefore frequently referred to specialists or academic centers.
This creates networks in which a relatively limited number of institutions influence a much broader patient population.
Understand Referral Networks
Commercial planning should examine where patients first enter care, which physicians suspect the disease, who confirms diagnosis, when referral occurs and where patients ultimately receive treatment. This helps identify the true decision network.
Medical Affairs Implications
Centers of Excellence frequently participate in research, clinical trials, publications, education and guideline development. Scientific engagement should therefore begin before commercial launch activity.
Commercial Implications
Understanding Centers of Excellence can influence field-force structure, account strategy, physician segmentation, patient identification, educational priorities and geographic coverage—especially for neurology rare disease and endocrinology rare disease markets.
Patient Access Implications
Patients may live significant distances from specialist centers. Commercialization must therefore consider travel, treatment logistics, local coordination, specialty pharmacy, reimbursement and patient support.
Think in Networks
Rare disease commercialization is rarely simply a matter of assigning representatives to territories. It requires understanding networks of influence, referral and care. Those networks should be mapped early.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
